

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises:

- (a) measuring in the mammal the level of ~~at least one~~ a biomarker selected from the biomarkers of Table 4 comprising mucin 2;
- (b) exposing the mammal to the EGFR modulator;
- (c) following the exposing of step (b), measuring in the mammal the level of the ~~at least one~~ biomarker, wherein a difference in the level of the ~~at least one~~ biomarker measured in step (c) compared to the level of the ~~at least one~~ biomarker measured in step (a) indicates that the mammal will respond therapeutically to said method of treating cancer.

Claim 2 (canceled)

Claim 3 (currently amended): The method of claim 1 wherein the method is an in vitro method, and wherein the ~~at least one~~ biomarker is measured in at least one mammalian biological sample from the mammal.

Claim 4 (currently amended): A method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises:

- (a) exposing the mammal to the EGFR modulator;
- (b) following the exposing of step (a), measuring in the mammal the level of ~~the at least one~~ a biomarker selected from the biomarkers of Table 4 comprising mucin 2, wherein a difference in the level of the ~~at least one~~ biomarker measured in step (b), compared to the level of the biomarker in a mammal that has not been exposed to said EGFR modulator, indicates that the mammal will respond therapeutically to said method of treating cancer.